Loading organizations...
Numerate has raised $14.0M across 2 funding rounds.
Key people at Numerate.
Numerate has raised $14.0M in total across 2 funding rounds.
Numerate develops an AI-driven drug engineering platform transforming small molecule drug discovery. Its in silico platform integrates proprietary machine learning algorithms and cloud computing with medicinal chemistry principles. This technology accelerates hit finding, lead design, optimization, and ADME prediction, directly addressing critical inefficiencies in pharmaceutical research and development.
Numerate was founded in 2007 by CEO Guido Lanza. The company originated from the insight that advanced computational methods and data science could dramatically improve drug discovery, traditionally hindered by high costs and low success rates. Lanza recognized the potential for a systematic, data-driven approach to rapidly optimize drug candidates.
The platform serves pharmaceutical companies and research institutions aiming for enhanced efficiency in drug development pipelines. Numerate’s vision is to fundamentally reshape new therapeutics discovery and advancement. The company strives to make bringing vital medications to patients significantly faster, more predictable, and ultimately more successful.
Numerate has raised $14.0M in total across 2 funding rounds.
Numerate's investors include Atlas Venture, UP.Partners.
Numerate has raised $14.0M across 2 funding rounds. Most recently, it raised $8.0M Series C in June 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2014 | $8M Series C | — | Atlas Venture | Announced |
| Feb 1, 2009 | $6M Series B | — | UP.Partners | Announced |
Key people at Numerate.
# Numerate: Computational Drug Discovery at Cloud Scale
Numerate is a computational drug design company that applies artificial intelligence and machine learning at cloud scale to accelerate small molecule drug discovery.[1][2] Founded in 2007, the company transforms how new medicines are discovered by combining advances in computer science and statistics with traditional medicinal chemistry approaches.[1] Rather than building drugs itself, Numerate provides a platform that helps pharmaceutical companies overcome major challenges in candidate selection and optimization, significantly reducing both timelines and capital investment in drug development.
The company focuses its therapeutic pipeline on cardiovascular, metabolic, and neurodegenerative diseases, targeting emerging therapeutic gaps and first-in-class opportunities.[1] Numerate was acquired by Valo Health on September 25, 2020, integrating into a broader ecosystem of computational drug discovery platforms.[2]
Numerate was founded in 2007 in San Francisco, emerging during the early wave of computational biology and cloud computing adoption.[1][2] The company's founding reflected a fundamental insight: that the combination of vast computational power, growing drug discovery datasets, and proprietary AI algorithms could fundamentally reshape how pharmaceutical candidates are identified and optimized.
A pivotal moment in the company's evolution came with its acquisition of DeepCrystal's small molecule design platform, which brought graph-valued deep-learning technology into Numerate's toolkit.[4] This acquisition brought Patrick Hop, DeepCrystal's founder, to Numerate as Principal Engineer of Deep Learning, strengthening the company's technical depth in applying advanced machine learning to drug discovery.[4]
Numerate operates at the intersection of three powerful trends: the AI revolution in life sciences, the shift toward computational-first drug discovery, and the maturation of cloud infrastructure enabling large-scale molecular modeling. The company exemplifies how machine learning is moving upstream in pharmaceutical R&D—from clinical trial optimization to the earliest stages of molecular design.
The timing has been particularly favorable: as drug discovery costs have escalated and success rates have stagnated, computational approaches have gained credibility with major pharmaceutical companies. Numerate's acquisition by Valo Health signals institutional validation of this model, positioning the company within a larger network of computational drug discovery platforms reshaping how the industry approaches therapeutic innovation.
Numerate represents a fundamental shift in pharmaceutical R&D economics—replacing trial-and-error with data-driven molecular design. As AI capabilities continue advancing and pharmaceutical companies face mounting pressure to reduce development costs and timelines, platforms like Numerate become increasingly central to competitive advantage.
The company's future likely involves deeper integration with Valo Health's broader computational ecosystem, expansion into additional therapeutic areas, and continued refinement of its deep-learning capabilities. The acquisition of DeepCrystal suggests Numerate will continue absorbing complementary technologies to strengthen its platform. As the pharmaceutical industry increasingly recognizes that computational drug discovery is not a niche capability but a fundamental requirement for competitive R&D, Numerate's influence on how medicines are discovered will only deepen.
